Literature DB >> 20560798

Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.

Xiaopei Huang1, Yiping Yang.   

Abstract

IMPORTANCE OF THE FIELD: Toll-like receptors (TLRs) are innate immune receptors critical in the innate immune defense against invading pathogens. Recent advances also reveal a crucial role for TLRs in shaping adaptive immune responses, conferring a potential therapeutic value to their modulation in the treatment of diseases. AREAS COVERED IN THIS REVIEW: The aim of this review is to discuss TLR9, the TLR9-MyD88 signaling pathway and its role in regulation of adaptive immune responses, as well as potential therapeutic implications by targeting this pathway. WHAT THE READER WILL GAIN: This review shows that the TLR9-MyD88 signaling pathway plays a critical role in promoting adaptive immune responses and that modulation of this pathway may have enormous therapeutic potential in enhancing vaccine potency, controlling autoimmunity, as well as improving the outcome of viral-vector-mediated gene therapy. TAKE HOME MESSAGE: Although TLR9 agonists have been used as adjuvants for enhancing vaccine potency, further exploitation of the TLR9-MyD88 pathway and its dynamic interaction with the immune system in vivo is needed to provide more effective therapeutic inventions in the design of vaccines for infectious diseases, allergies and cancer, in the control of autoimmunity, as well as in the improvement of viral-vector-mediated gene therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560798      PMCID: PMC2917181          DOI: 10.1517/14728222.2010.501333

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  104 in total

Review 1.  Innate immune recognition of viruses and viral vectors.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Hum Gene Ther       Date:  2009-04       Impact factor: 5.695

Review 2.  Multiscale analysis of T cell activation: correlating in vitro and in vivo analysis of the immunological synapse.

Authors:  Michael L Dustin
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

3.  The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation.

Authors:  Tobias Haas; Jochen Metzger; Frank Schmitz; Antje Heit; Thomas Müller; Eicke Latz; Hermann Wagner
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

Review 4.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Authors:  Jörg Vollmer; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2009-01-13       Impact factor: 15.470

5.  Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation.

Authors:  Ian Horkheimer; Michael Quigley; Jiangao Zhu; Xiaopei Huang; Nelson J Chao; Yiping Yang
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

Review 6.  Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.

Authors:  Arthur M Krieg; Jörg Vollmer
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

7.  The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

8.  TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions.

Authors:  Faihaa Hkima Abou Fakher; Nicolas Rachinel; Martine Klimczak; Jacques Louis; Noëlle Doyen
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

9.  Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.

Authors:  Christofer Samuelsson; Jürgen Hausmann; Henning Lauterbach; Michaela Schmidt; Shizuo Akira; Hermann Wagner; Paul Chaplin; Mark Suter; Meredith O'Keeffe; Hubertus Hochrein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.

Authors:  Ken J Ishii; Tatsukata Kawagoe; Shohei Koyama; Kosuke Matsui; Himanshu Kumar; Taro Kawai; Satoshi Uematsu; Osamu Takeuchi; Fumihiko Takeshita; Cevayir Coban; Shizuo Akira
Journal:  Nature       Date:  2008-02-07       Impact factor: 49.962

View more
  22 in total

Review 1.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

2.  Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies.

Authors:  Wei Zhang; Seong-Min Lim; Juyoung Hwang; Srinivasan Ramalingam; Myunghee Kim; Jun-O Jin
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

3.  Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation.

Authors:  Todd V Brennan; Liwen Lin; Xiaopei Huang; Diana M Cardona; Zhiguo Li; Keith Dredge; Nelson J Chao; Yiping Yang
Journal:  Blood       Date:  2012-07-03       Impact factor: 22.113

Review 4.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Authors:  A Ray; Z Tian; D S Das; R L Coffman; P Richardson; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

6.  The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

Authors:  Francesca Gilli; Libin Li; Andrew R Pachner
Journal:  J Neurovirol       Date:  2015-08-11       Impact factor: 2.643

7.  TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.

Authors:  John S S Butterfield; Moanaro Biswas; Jamie L Shirley; Sandeep R P Kumar; Alexandra Sherman; Cox Terhorst; Chen Ling; Roland W Herzog
Journal:  Hum Gene Ther Methods       Date:  2019-06       Impact factor: 2.396

8.  Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.

Authors:  Brian J Ward; Philipe Gobeil; Annie Séguin; Judith Atkins; Iohann Boulay; Pierre-Yves Charbonneau; Manon Couture; Marc-André D'Aoust; Jiwanjeet Dhaliwall; Carolyn Finkle; Karen Hager; Asif Mahmood; Alexander Makarkov; Matthew P Cheng; Stéphane Pillet; Patricia Schimke; Sylvie St-Martin; Sonia Trépanier; Nathalie Landry
Journal:  Nat Med       Date:  2021-05-18       Impact factor: 53.440

9.  Targeting co-stimulatory pathways in gene therapy.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Front Microbiol       Date:  2011-09-28       Impact factor: 5.640

10.  Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy.

Authors:  Thais B Bertolini; Jamie L Shirley; Irene Zolotukhin; Xin Li; Tsuneyasu Kaisho; Weidong Xiao; Sandeep R P Kumar; Roland W Herzog
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.